ORIGINAL RESEARCH article
Front. Oncol.
Sec. Gastrointestinal Cancers: Hepato Pancreatic Biliary Cancers
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1601140
This article is part of the Research TopicNovel Molecular Targets in Cancer TherapyView all 48 articles
A pan-cancer perspective analysis reveals the prognostic significance of SLC7A11 in hepatocellular carcinoma
Provisionally accepted
- 1First Affiliated Hospital of Jinzhou Medical University, Jinzhou, Liaoning Province, China
- 2Department of Oncology, First Affiliated Hospital of Jinzhou Medical University, Jinzhou, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
To investigate the role of SLC7A11 in hepatocellular carcinoma (HCC) and its potential as a prognostic biomarker. Immunohistochemistry (IHC) was used to assess SLC7A11 expression in clinical HCC tissues. Prognostic value was analyzed alongside clinical factors. Pan-cancer analysis explored SLC7A11 expression, mutation signatures, and functional enrichment. Data from The Cancer Genome Atlas (TCGA) were utilized to study the impact of SLC7A11 on tumor microenvironment, tumor mutation burden (TMB), and drug sensitivity. SLC7A11 was significantly upregulated in HCC tissues, correlating with poorer survival. Similar findings were observed in multiple cancers, with a common missense mutation (G>A) in SLC7A11. Elevated SLC7A11 expression correlated with higher TMB and TIDE scores; enrichment in transport/metabolic pathways; and increased M0 macrophage infiltration. It also correlated positively with immune related scores and sensitivity to certain drugs (Gemcitabine, AZD7762, Bortezomib, Vinorelbine) but negatively with tumor purity and sensitivity to others (AZD6482, Cisplatin, Nilotinib). SLC7A11 expression correlates with poor prognosis and may inform HCC treatment strategies, though mechanistic validation is needed.
Keywords: SLC7A11, Hepatocellular Carcinoma, Tumor Microenvironment, prognostic biomarker, ferroptosis
Received: 27 Mar 2025; Accepted: 18 Aug 2025.
Copyright: © 2025 Zhang, Wang, Chen, Wang, Zhang and Liu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Xiaomei Liu, Department of Oncology, First Affiliated Hospital of Jinzhou Medical University, Jinzhou, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.